echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > PNAS: A common antihypertensive drug delivered directly to the inner membrane of the mitochondria

    PNAS: A common antihypertensive drug delivered directly to the inner membrane of the mitochondria

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In a study conducted using lab-grown cells, researchers at Johns Hopkins Medicine who specialize in aging reported that they had successfully delivered a common antihypertensive drug directly to the lining of mitochondria, the "power plants" in human, animal, plant and most other biological cells
    .


    Researchers have long aimed to develop ways to deliver drugs directly against these energy-producing parts of cells because mitochondria drive, control, or play a role in almost every biological process, including the natural death and aging
    of cells.


    The new study, published Aug.


    Peter Abadir, MD, associate professor of geriatrics and gerontology at Johns Hopkins University School of Medicine, said: "Our study shows that we can use the body's natural mitochondrial transport system to deliver drugs
    more precisely.


    In this study, the researchers synthesized three natural transporters
    that interact with mitochondria in the lab.


    In a proof-of-concept experiment, the researchers also tested a "scrambled" version of mtLOS, which cannot penetrate cell membranes
    .


    Further research is needed, Abadir said, but the goal is to use mtLOS or other natural transport routes to directly and effectively target biochemical imbalances and loss of delivery drugs
    associated with chronic inflammation, aging and weakened organ function characteristic of many diseases.


    Abadil said: "We know that part of the reason people age is mitochondrial decline, and for decades scientists have been trying to counteract this decline
    with treatments that go directly into the organelles.


    Han, Jeremey Walston, Peter Abadir and Ran Lin have filed two patents
    based on the study.


    Other scientists who contributed to the study include Jude Phillip, Lin Ran, Andrew Chissham, David Stern, Li Yukang, Yuzhu Wang, Han Wang, David Rini, Cui Honggang and Jeremy Walston
    of Johns Hopkins University.


    The study was funded
    by the Johns Hopkins University Independent Center for the American Elderly, the National Institute of Aging-National Institutes of Health, the Johns Hopkins University School of Medicine Discovery Fund Project - Synergy Award, the Nathan W.


    Journal Reference:

    1. Jude M Phillip, Ran Lin, Andrew Cheetham, David Stern, Yukang Li, Yuzhu Wang, Han Wang, David Rini, Honggang Cui, Jeremy D Walston, Peter M Abadir.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.